Terms: = Breast cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
1159 results:
1. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with cdk4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract] [Full Text] [Related]
2. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract] [Full Text] [Related]
3. Visceral crisis in metastatic breast cancer: an old concept with new perspectives.
Andrade MO; Bonadio RRDCC; Diz MDPE; Testa L
Clinics (Sao Paulo); 2024; 79():100362. PubMed ID: 38754225
[TBL] [Abstract] [Full Text] [Related]
4. [Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer].
Liu B; Yuan Y; Li F; Li JB; Bian L; Wang T; Zhang SH; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1507-1513. PubMed ID: 38706058
[No Abstract] [Full Text] [Related]
5. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells.
Favaretto G; Rossi MN; Cuollo L; Laffranchi M; Cervelli M; Soriani A; Sozzani S; Santoni A; Antonangeli F
Cancer Immunol Immunother; 2024 May; 73(6):113. PubMed ID: 38693312
[TBL] [Abstract] [Full Text] [Related]
6. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
7. Doses to the right coronary artery and the left anterior descending coronary artery and death from ischemic heart disease after breast cancer radiotherapy: a case-control study in a population-based cohort.
Perman M; Johansson KA; Holmberg E; Karlsson P
Acta Oncol; 2024 Apr; 63():240-247. PubMed ID: 38682458
[TBL] [Abstract] [Full Text] [Related]
8. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving cdk4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
9. Overcoming BRAF and cdk4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
10. Predicting drug-drug interactions in breast cancer patients treated with cdk4/6 inhibitors and forward planning.
Kulkarni A; Singh J
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):225-233. PubMed ID: 38600865
[TBL] [Abstract] [Full Text] [Related]
11. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials.
Apostolidou K; Zografos E; Papatheodoridi MA; Fiste O; Dimopoulos MA; Zagouri F
Breast; 2024 Jun; 75():103729. PubMed ID: 38599049
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies cdk4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors.
Magrath JW; Sampath SS; Flinchum DA; Hartono AB; Goldberg IN; Boehling JR; Savkovic SD; Lee SB
Cancer Res; 2024 May; 84(9):1426-1442. PubMed ID: 38588409
[TBL] [Abstract] [Full Text] [Related]
13. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK; Abolhassani A; Guy L; Elshazly AM; Barrett JT; Mivechi NF; Gewirtz DA; Schoenlein PV
Front Endocrinol (Lausanne); 2024; 15():1298423. PubMed ID: 38567308
[TBL] [Abstract] [Full Text] [Related]
14. Estrogen receptor regulation of the immune microenvironment in breast cancer.
McGuinness C; Britt KL
J Steroid Biochem Mol Biol; 2024 Jun; 240():106517. PubMed ID: 38555985
[TBL] [Abstract] [Full Text] [Related]
15. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
16. A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced breast cancer.
Ardavanis-Loukeris G; Kokkali S; Perdikari K; Karatrasoglou E; Talagani S; Tzovaras A; Ardavanis A
Anticancer Res; 2024 Apr; 44(4):1559-1565. PubMed ID: 38537957
[TBL] [Abstract] [Full Text] [Related]
17. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
18. A rare case of Takotsubo cardiomyopathy.
Fiste O; Trika C; Syrigos NK; Kotteas EA
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2063-2067. PubMed ID: 38497887
[TBL] [Abstract] [Full Text] [Related]
19. PRMT5 is an actionable therapeutic target in cdk4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract] [Full Text] [Related]
20. Impact of HER2-low expression on the efficacy of endocrine therapy with or without cdk4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
[TBL] [Abstract] [Full Text] [Related]
[Next]
